{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:24Z","timestamp":1792887804863,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007543","name":"National Agency for Safety of Medicines and Health Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinph.2025.2110987","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:22:48Z","timestamp":1756221768000},"page":"2110987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cumulative motor index in spinal muscular atrophy after gene therapy: baseline predicts maximal recovery"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-5035","authenticated-orcid":false,"given":"R\u00e9mi","family":"Barrois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Barnerias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Deladri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Fauroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1942-4627","authenticated-orcid":false,"given":"Lucie","family":"Griffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-5021","authenticated-orcid":false,"given":"Sonia","family":"Khirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Poirault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Gitiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinph.2025.2110987_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.clinph.2025.2110987_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/acn3.23","article-title":"Electrophysiological biomarkers in spinal muscular atrophy: proof of concept","volume":"1","author":"Arnold","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cnp.2024.04.002","article-title":"Revisiting the compound muscle action potential (CMAP)","volume":"9","author":"Barkhaus","year":"2024","journal-title":"Clin. Neurophysiol. Pract."},{"key":"10.1016\/j.clinph.2025.2110987_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nmd.2023.02.004","article-title":"A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy","volume":"33","author":"Barrois","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0025","article-title":"Manual for the Bayley scales of infant development","author":"Bayley","year":"1969","journal-title":"Psychol. Corpor."},{"key":"10.1016\/j.clinph.2025.2110987_b0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.clinph.2025.2110987_b0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene abeparvovec: a review in spinal muscular atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinph.2025.2110987_b0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1242\/dmm.030148","article-title":"Therapeutic strategies for spinal muscular atrophy: SMN and beyond","volume":"10","author":"Bowerman","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.clinph.2025.2110987_b0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13023-024-03326-3","article-title":"Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment","volume":"19","author":"Desguerre","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clinph.2025.2110987_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.clinph.2025.2110987_b0070","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinph.2025.2110987_b0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.praneu.2022.04.005","article-title":"L\u2019\u00e9lectroneuromyographie chez l\u2019enfant, comment faire en pratique?","volume":"13","author":"Gitiaux","year":"2022","journal-title":"Pratique Neurol. - FMC"},{"key":"10.1016\/j.clinph.2025.2110987_b0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","article-title":"Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy","volume":"130","author":"G\u00fcnther","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.clinph.2025.2110987_b0090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/mus.23967","article-title":"The motor neuron response to SMN1 deficiency in spinal muscular atrophy","volume":"49","author":"Kang","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2025.2110987_b0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen","volume":"92","author":"Kariyawasam","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clinph.2025.2110987_b0100","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile\u2010onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal Muscular Atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.clinph.2025.2110987_b0120","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2025.2110987_b0125","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.clinph.2025.2110987_b0130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinph.2025.2110987_b0135","series-title":"Pediatric Electromyography","author":"McMillan","year":"2017"},{"key":"10.1016\/j.clinph.2025.2110987_b0140","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinph.2025.2110987_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WNP.0000000000000116","article-title":"Cumulative motor index: an index to study progression of amyotrophic lateral sclerosis","volume":"32","author":"Nandedkar","year":"2015","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.clinph.2025.2110987_b0160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O\u2019Hagen","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nmd.2019.03.003","article-title":"Thoracic circumference: a new outcome measure in spinal muscular atrophy type 1?","volume":"29","author":"Ropars","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clinph.2025.2110987_b0170","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1212\/WNL.0000000000205694","article-title":"RAINBOWFISH: primary efficacy and safety data in risdiplam-treated infants with presymptomatic Spinal Muscular Atrophy (SMA) (S37.006)","volume":"102","author":"Servais","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.clinph.2025.2110987_b0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clinph.2025.2110987_b0180","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.clinph.2025.2110987_b0185","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"10.1016\/j.clinph.2025.2110987_b0190","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinph.2025.2110987_b0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adol. Health"}],"container-title":["Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245725008399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245725008399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:52:40Z","timestamp":1762545160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245725008399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"alternative-id":["S1388245725008399"],"URL":"https:\/\/doi.org\/10.1016\/j.clinph.2025.2110987","relation":{},"ISSN":["1388-2457"],"issn-type":[{"value":"1388-2457","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cumulative motor index in spinal muscular atrophy after gene therapy: baseline predicts maximal recovery","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinph.2025.2110987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"2110987"}}